Program
zaltenibart
Also written as “OMS906 study drug” and “OMS906”.
Its studies are mostly in Hemoglobinuria, Paroxysmal · Glomerulonephritis, led by Omeros.
Furthest: phase 2, since Jul 11, 20234 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Omeros | 41 open or running | phase 2since Jul 11, 2023 | May 4, 2023 | Dec 2026phase 2 · NCT06298955 |
- Named in novo nordisk’s own pipeline as
Zaltenibart in PNH
, phase 2, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 4, 2023First study: phase 1 study in Hemoglobinuria, ParoxysmalFirst studyNCT05889299 · 15 enrolled · Ukraine
- Jul 11, 2023Phase 2 study in Hemoglobinuria, ParoxysmalNCT05972967 · 12 enrolled · Germany, Greece, Switzerland and more
- Jan 4, 2024Phase 2 study in C3 GlomerulopathyNCT06209736 · 3 enrolled · Lithuania, New Zealand, Poland and more
- Feb 17, 2024Phase 2 study in Hemoglobinuria, ParoxysmalNCT06298955 · 25 enrolled · Germany, Switzerland, Ukraine and more
- Nov 2, 2026Phase 2 study terminatedStudy stoppedNCT06209736 · “The study was terminated for strategic reasons related to the molecule's recent acquisition”
Ahead
- Dec 2026Primary completion: phase 2 study in Hemoglobinuria, ParoxysmalNCT06298955
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06298955Hemoglobinuria, Paroxysmal · Germany, Switzerland, Ukraine and more | 2 | Active, not recruiting | Dec 2026 | 25 |
| NCT06209736C3 Glomerulopathy · Lithuania, New Zealand, Poland and more | 2 | Terminated | Apr 14, 2026 | 3 |
| NCT05972967Hemoglobinuria, Paroxysmal · Germany, Greece, Switzerland and more | 2 | Completed | Oct 10, 2024 | 12 |
| NCT05889299Hemoglobinuria, Paroxysmal · Ukraine | 1 | Completed | Nov 3, 2025 | 15 |
How it is read
Names in the registry
- “OMS906 study drug”, 2 entries
- “OMS906”, 2 entries
Conditions, from the studies’ own filings
- Hemoglobinuria, Paroxysmal, 3 studies
- Glomerulonephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.